What’s the current market cap for STERIS stock?

STERIS (STE) has a market cap of $21B as of May 28, 2026.

What is the P/E ratio for STERIS stock?

The price to earnings (P/E) ratio for STERIS (STE) stock is 27.27 as of May 28, 2026.

Does STERIS stock pay dividends?

Yes, the STERIS (STE) stock pays dividends to shareholders. As of May 28, 2026, the dividend rate is $2.46 and the yield is 1.17%. STERIS has a payout ratio of 30.91% on a trailing twelve-month basis.

When is the next STERIS dividend payment date?

The next STERIS (STE) dividend payment is scheduled for June 26, 2026.

What is the beta indicator for STERIS ?

STERIS (STE) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy STERIS stock | $STE Share Price

13:30

15:10

16:45

18:25

20:00

About STERIS

Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.

Ticker

$STE

Sector

Health

Primary listing

NYSE

Employees

17,787

Headquarters

Mentor, United States

Website

www.steris.com

STERIS Metrics

BasicAdvanced

$21bn

27.27

$7.93

0.95

$2.46

1.17%

What the Analysts think about STERIS

Analyst ratings (Buy, Hold, Sell) for STERIS stock.

Bulls say / Bears say

Steris increased its fiscal 2026 adjusted EPS outlook to $10.15–$10.30, exceeding the consensus of $10.09, and raised its constant-currency organic revenue growth forecast to 7–8%, fueled by strong demand momentum (Reuters)

In Q2, Steris delivered 10% revenue growth to $1.50 billion, and its adjusted EPS of $2.47 topped the $2.35 estimate, resulting in better-than-expected profit and free cash flow (Reuters)

Life Sciences division revenue jumped 13%, led by a 39% surge in capital equipment sales, demonstrating broad-based growth across all business areas (Reuters)

Tariff-related costs and inflation are eroding the healthcare segment's growth, continuing to pressure operating margins (Reuters)

Capital equipment sales in Applied Sterilization Technologies fell, even as service revenues rose, highlighting possible volatility in equipment demand (Reuters)

Steris is valued at a high multiple—about 30.7× P/E and 14.8× EV/EBITDA—so the shares assume near-perfect execution, leaving little margin for error (EveryTicker)

Data summarised monthly by Lightyear AI. Last updated on 29 Apr 2026.

STERIS Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

STERIS Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $STE

Capital at risk

Market closed

Upcoming events